S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Why Turkey's currency is crashing after Erdogan got reelected
BREAKING: Tiny biotech successfully treats blindness (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Why Turkey's currency is crashing after Erdogan got reelected
BREAKING: Tiny biotech successfully treats blindness (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Why Turkey's currency is crashing after Erdogan got reelected
BREAKING: Tiny biotech successfully treats blindness (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Why Turkey's currency is crashing after Erdogan got reelected
BREAKING: Tiny biotech successfully treats blindness (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
NASDAQ:NVAX

Novavax (NVAX) Stock Forecast, Price & News

$7.47
-0.22 (-2.86%)
(As of 06/9/2023 ET)
Compare
Today's Range
$7.45
$8.20
50-Day Range
$6.89
$9.52
52-Week Range
$5.61
$76.77
Volume
5.51 million shs
Average Volume
6.27 million shs
Market Capitalization
$644.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.67

Novavax MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
585.4% Upside
$51.20 Price Target
Short Interest
Bearish
36.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
0.24mentions of Novavax in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$6,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.76) to ($1.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

422nd out of 987 stocks

Biological Products, Except Diagnostic Industry

65th out of 156 stocks


NVAX stock logo

About Novavax (NASDAQ:NVAX) Stock

Novavax Inc is a biotechnology company that focuses on developing vaccines and biological therapies that combat infectious diseases. The company is headquartered in Gaithersburg, Maryland and has several locations across the United States and Europe. Novavax has a strong track record of developing novel vaccine candidates and has achieved significant milestones in recent years.

In 2020 the company redirected all efforts into finding a vaccine for the COVID-19 pandemic releasing its NVX-CoV2373 vaccine called Nuvaxovid, which has been approved for use in the European Union and Canada. 

Novavax Inc's team is led by CEO John C. Jacobs, who was appointed CEO and board member in Q1 of 2023. Mr. Jacobs has over 25 years of commercial and business operation skills and has demonstrated leadership across multiple therapeutic areas. Mr. Jacobs previously served as CEO and board member at Harmony Biosciences, where he served for five years, leading that company through a successful initial public offering (IPO).

Other notable team members include Dr. Gregory Glenn, the President of Research and Development, with 28 years of vaccine design and regulatory experience. Also noteworthy is Dr. Filip Dubovsky, Novavax Inc's Executive Vice President and Chief Medical Officer, a recognized leader in vaccine development and who joined the company after a 15-year tenure at AstraZeneca, another leading vaccine manufacturer. 

Over the past few years, Novavax has reported steady revenue growth. The company's revenue has increased year over year, reporting net income up each year since 2021. The company's debt levels are high, with total liabilities exceeding total assets for multiple years. Novavax's valuation metrics are in line with industry peers. The company's price-to-earnings ratio and the company's price-to-book ratio are in line with industry peers.

These metrics suggest that the market is valuing Novavax appropriately. Novavax's stock performance has been volatile in recent years. The company's stock price increased significantly in 2020 due to its COVID-19 vaccine development efforts. However, the stock price has since declined, as Novavax has faced delays in obtaining regulatory approvals for its COVID-19 vaccine. Despite these setbacks, the company's long-term prospects remain strong.

The vaccine industry is highly competitive and has significant regulatory and political risks. Novavax faces competition from established pharmaceutical companies, as well as other biotechnology companies that are developing vaccines. However, the company's focus on innovative vaccine candidates, such as its COVID-19 vaccine, gives it a competitive advantage. The vaccine industry is also subject to regulatory risks, as government policy changes can significantly impact the market. Novavax's strong relationships with regulatory agencies give it an advantage in navigating this challenging environment.

Novavax has several growth opportunities in the near term. The company's COVID-19 vaccine has shown promising results in clinical trials and has received regulatory approval in multiple markets. Novavax also has several other vaccine candidates in development, including respiratory syncytial virus (RSV) and influenza vaccines. The company's pipeline of innovative vaccine candidates positions it for long-term growth and success.

Novavax faces several risks and challenges that could impact its long-term success. The company's vaccine candidates are subject to regulatory approval, which can be lengthy and expensive. Novavax also faces significant competition from established pharmaceutical companies and other biotechnology companies. Changes in consumer preferences or shifts in government policies could also impact the market for Novavax's products. 

Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Stock News Headlines

Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea
Novavax (NASDAQ:NVAX) Raised to "Hold" at StockNews.com
Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
Brokerages Set Novavax, Inc. (NASDAQ:NVAX) PT at $79.00
Novavax (NASDAQ: NVAX)
Novavax (NASDAQ:NVAX) Stock Price Down 7.7%
Novavax (NASDAQ:NVAX) Trading Up 6.5%
Novavax: Sell The Covid Rips
See More Headlines

NVAX Price History

NVAX Company Calendar

Last Earnings
5/09/2023
Today
6/09/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,992
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$51.20
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+846.0%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-657,940,000.00
Pretax Margin
-84.81%

Debt

Sales & Book Value

Annual Sales
$1.98 billion
Book Value
($8.08) per share

Miscellaneous

Free Float
85,528,000
Market Cap
$644.74 million
Optionable
Optionable
Beta
1.72

Social Links


Key Executives

  • John C.s Jacobs
    President, Chief Executive Officer & Director
  • Richard Crowley
    Chief Operating Officer & Executive Vice President
  • James Patrick Kelly
    Chief Financial Officer, Treasurer & Executive VP
  • Gale E. Smith
    Chief Scientist & Senior Vice President-Discovery
  • Biegie Lee
    Chief Information Officer & Senior Vice President













NVAX Stock - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVAX, but not buy additional shares or sell existing shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price forecast for 2023?

6 Wall Street research analysts have issued 1-year price targets for Novavax's stock. Their NVAX share price forecasts range from $27.00 to $110.00. On average, they predict the company's stock price to reach $51.20 in the next twelve months. This suggests a possible upside of 585.4% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2023?

Novavax's stock was trading at $10.28 at the beginning of 2023. Since then, NVAX shares have decreased by 27.3% and is now trading at $7.47.
View the best growth stocks for 2023 here
.

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our NVAX earnings forecast
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($3.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.38) by $0.03. The biopharmaceutical company earned $81 million during the quarter, compared to analyst estimates of $94.52 million. The firm's revenue was down 88.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.56 earnings per share.

When did Novavax's stock split?

Shares of Novavax reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.40 billion-$1.60 billion, compared to the consensus revenue estimate of $831.60 million.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (12.86%), BlackRock Inc. (5.53%), Shah Capital Management (4.93%), Renaissance Technologies LLC (4.10%), Citigroup Inc. (0.00%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends
.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $7.47.

How much money does Novavax make?

Novavax (NASDAQ:NVAX) has a market capitalization of $644.74 million and generates $1.98 billion in revenue each year. The biopharmaceutical company earns $-657,940,000.00 in net income (profit) each year or ($14.37) on an earnings per share basis.

How many employees does Novavax have?

The company employs 1,992 workers across the globe.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -